APRE News and Press, Aprea Therapeutics Inc. From 01/02/21

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. A drifting New Year's Eve stock market kicked into bullish mode in the last two hours of trading Thursday, helping the S&P 500 and the Do...

Gainers: ATIF Holdings (ATIF) +85%.Greenpro Capital (GRNQ) +77%.Bit Digital (BTBT) +67%.Avalon Holdings (AWX) +53%.Euro Tech Holdings Company (CLWT) +48%.Poseida Therapeutics (PSTX) +44%.Peabody Energy (BTU) +42%.Flux Power Holdings (FLUX) +39%.DPW Holdings (DPW) +37%.Marine Petroleum Trust (...

The small-cap biopharmaceutical company, Aprea Therapeutics (APRE) drops 74.2% in premarket trading as the company announces that its lead therapeutic candidate, eprenetapopt, has failed in a Phase 3 trial for myelodysplastic syndrome.Involving 154 TP53 mutant MDS patients...

Aprea Therapeutics' (APRE) late-stage trial of its cancer combo treatment failed to meet the main goal of complete remission ((CR)) rate in patients with a form of myelodysplastic syndrome.The study aims to test the safety and efficacy of eprenetapopt with azacitidine ((AZA)) versus AZA alone...

The trial failed to meet its primary endpoint of complete remission (CR) rate CR rate was 53% higher in eprenetapopt with AZA arm compared to AZA alone, but did not reach statistical significance BOSTON, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE)...

The FDA grants Fast Track status to Aprea Therapeutics' (APRE) eprenetapopt for the treatment of acute myeloid leukemia ((AML)).Fast Track provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.Small molecule eprenetapopt reactivates ...

BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Admin...

Healthcare stocks have a rich history of churning out big winners. The sector has been a hotbed of innovation over the past decade, leading to breakthrough treatments for a variety of hard-to-treat cancers, rare diseases, and chronic illnesses like arthritis and diabetes, among many others....

BOSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that Christian S. Schade, Chairma...

Aprea Therapeutics (APRE): Q3 GAAP EPS of -$0.58 beats by $0.16.Ccash and cash equivalents of $101.1M.Press Release For further details see: Aprea Therapeutics EPS beats by $0.16